<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput xmlns:ns2="local" id="85890" name="RBX-2660"><HDS>Phase 3 Clinical</HDS><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><Actions><Action id="1594" type="secondary">Antibacterial</Action><Action id="173474" type="secondary">Microbiome modulator</Action><Action id="59620" type="secondary">Unspecified drug target</Action></Actions><Indications><Indication id="1481" type="primary">Enterococcus infection</Indication><Indication id="2528" type="primary">Hepatic encephalopathy</Indication><Indication id="337" type="primary">Ulcerative colitis</Indication><Indication id="758" type="primary">Multidrug resistant infection</Indication><Indication id="995" type="primary">Clostridium difficile infection</Indication></Indications><Entities><Entity>Biological</Entity></Entities><OriginatorCompany id="1084556">Rebiotix Inc</OriginatorCompany></ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput>